Fewer than one in 10 patients eligible to benefit from obesity jabs including Wegovy can access them, states the World Health Organization as it releases its first recommendations on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging more widespread and fairer access to this class of drugs.
Per estimates, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The latest guidance affirms that excess weight is a long-term condition that can be addressed with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant obstacles to universal access to the injections that can assist patients in reducing significant body mass, notes the agency.
Weight-Loss Drug Supply Crisis
Even in the current most optimistic scenario, the production of these medications could only cover around 100 million people – fewer than 10% of the global need, according to the WHO.
The advice encourages nations and manufacturers to expand access, through approaches like voluntary licensing.
A patent on the active ingredient – the primary ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Drugs Work
The injections replicate a natural hormone to slow digestion, suppress the appetite and enhance the sense of being full so people reduce food intake.
People typically begin shedding pounds in the initial weeks of starting on the weekly injections.
Research points to people may see weight return within a year of stopping the medication, because their usual appetite come back.
Being above a healthy weight raises your chance for developing diseases, such as type 2 diabetes, heart disease, brain attack, and specific malignancies.
Excess weight impacts people in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the WHO.
